The TGA has revised the acceptable intake limits for nitrosamine impurities to align with EMA guidelines. Affected sponsors and manufacturers must review their products to ensure they meet the new AI limits.
Failure to comply with the updated AI limits may result in non-compliance with safety regulations and could jeopardize product approvals and market access.
Manufacturers must evaluate their products against the new thresholds and update their risk management plans (RMPs) and risk-based monitoring protocols if any exceed the limits.
Regulatory Intelligence Lead
Review before 2026-08-14.
Updates to established acceptable intake (AI) limits for specific nitrosamines; alignment of TGA standards with updated EMA recommendations.
Sponsors and manufacturers must review their products against the revised AI limits. PV teams should update risk management plans (RMPs) and risk-based monitoring protocols if any products exceed the new thresholds, ensuring compliance with updated safety expectations.
Manufacturers must evaluate their products against the new thresholds and update their risk management plans (RMPs) and risk-based monitoring protocols if any exceed the limits.
The Therapeutic Goods Administration (TGA) updated its guidance on acceptable intake (AI) limits for nitrosamine impurities in medicines, introducing revised limits for various impurities and aligning TGA standards with international recommendations. Sponsors and manufacturers are required to assess their products against these new thresholds and ensure compliance by updating risk management plans (RMPs) and monitoring protocols accordingly.
What changed: The TGA has revised the acceptable intake limits for nitrosamine impurities to align with EMA guidelines. Affected sponsors and manufacturers must review their products to ensure they meet the new AI limits.
Why it matters: Failure to comply with the updated AI limits may result in non-compliance with safety regulations and could jeopardize product approvals and market access.
Practical implication: Manufacturers must evaluate their products against the new thresholds and update their risk management plans (RMPs) and risk-based monitoring protocols if any exceed the limits.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
